Want to see IN:GLAXO full AI Analyst Report?
GLAXO Stock Chart & Stats
₹2483.35
-₹2.55(-0.12%)
At close: 4:00 PM EST
₹2483.35
-₹2.55(-0.12%)
Day’s Range― - ―
52-Week Range₹2,088.00 - ₹3,362.55
Previous CloseN/A
Volume25.42K
Average Volume (3M)1.83K
Market Cap
₹409.28B
Enterprise Value₹361.97B
Total Cash (Recent Filing)₹27.56B
Total Debt (Recent Filing)₹332.70M
Price to Earnings (P/E)39.5
Beta0.70
Next Earnings
Jul 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.16%
Share Statistics
EPS (TTM)61.15
Shares Outstanding169,406,040
10 Day Avg. Volume1,472
30 Day Avg. Volume1,831
Financial Highlights & Ratios
PEG Ratio3.20
Price to Book (P/B)17.06
Price to Sales (P/S)10.12
P/FCF Ratio39.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)69.53
Revenue Forecast (FY)₹42.07B
Bulls Say, Bears Say
Bulls Say
Improving ProfitabilitySustained margin improvement to ~27% net and ~33% EBIT indicates stronger operating leverage and/or a higher-margin product mix. Durable higher margins enhance cash generation, support reinvestment in brands and R&D, and improve return on equity over the medium term.
Conservative Balance SheetVery low leverage with debt-to-equity under ~2.3% gives the company flexibility to fund growth, tolerate shocks, and consider opportunistic M&A or buybacks without refinancing risk. High ROE shows efficient capital use and durable earnings power versus the equity base.
High-Quality Cash GenerationFCF tracking nearly one-to-one with net income signals earnings quality and real cash conversion. The recent step-up in FCF improves ability to fund capex, dividends, and lifecycle brand investment, reducing dependence on external financing over the medium term.
Bears Say
Profitability VolatilityHistorical swings, including a non-recurring >50% net margin in 2022, make baseline margin assumptions less reliable. This volatility complicates multi-quarter forecasting, can mask structural margin trends, and raises the risk that future profits could lapse if transient gains reverse.
Working-Capital VariabilityWide swings in operating cash conversion point to working-capital timing and collection or inventory variability. That can produce uneven free cash flow across periods, stress liquidity in downturns, and require active treasury management to maintain funding of operations.
Balance-Sheet Volatility HistoryA sharp prior decline in equity and assets suggests susceptibility to operational shocks or prior write-downs. Although rebuilt, recurrence would impair capital cushions and could limit flexibility to invest or absorb adverse regulatory or market events in the medium term.
GlaxoSmithKline Pharmaceuticals Limited News
GLAXO FAQ
What was GlaxoSmithKline Pharmaceuticals Limited’s price range in the past 12 months?
GlaxoSmithKline Pharmaceuticals Limited lowest stock price was ₹2088.00 and its highest was ₹3362.55 in the past 12 months.
What is GlaxoSmithKline Pharmaceuticals Limited’s market cap?
GlaxoSmithKline Pharmaceuticals Limited’s market cap is ₹409.28B.
When is GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date?
GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date is Jul 27, 2026 which is in 24 days.
How were GlaxoSmithKline Pharmaceuticals Limited’s earnings last quarter?
GlaxoSmithKline Pharmaceuticals Limited released its earnings results on May 13, 2026. The company reported ₹16.4 earnings per share for the quarter, beating the consensus estimate of N/A by ₹16.4.
Is GlaxoSmithKline Pharmaceuticals Limited overvalued?
According to Wall Street analysts GlaxoSmithKline Pharmaceuticals Limited’s price is currently Overvalued.
Does GlaxoSmithKline Pharmaceuticals Limited pay dividends?
GlaxoSmithKline Pharmaceuticals Limited pays a Annually dividend of ₹57 which represents an annual dividend yield of 2.16%. See more information on GlaxoSmithKline Pharmaceuticals Limited dividends here
What is GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate?
GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlaxoSmithKline Pharmaceuticals Limited have?
GlaxoSmithKline Pharmaceuticals Limited has 169,406,040 shares outstanding.
What happened to GlaxoSmithKline Pharmaceuticals Limited’s price movement after its last earnings report?
GlaxoSmithKline Pharmaceuticals Limited reported an EPS of ₹16.4 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.685%.
Which hedge fund is a major shareholder of GlaxoSmithKline Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:GLAXO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Technical Analysis
Cipla Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―
Torrent Pharmaceuticals Ltd
―